SG11202001458SA - Method for the safe induction of immunity against rsv - Google Patents

Method for the safe induction of immunity against rsv

Info

Publication number
SG11202001458SA
SG11202001458SA SG11202001458SA SG11202001458SA SG11202001458SA SG 11202001458S A SG11202001458S A SG 11202001458SA SG 11202001458S A SG11202001458S A SG 11202001458SA SG 11202001458S A SG11202001458S A SG 11202001458SA SG 11202001458S A SG11202001458S A SG 11202001458SA
Authority
SG
Singapore
Prior art keywords
immunity against
against rsv
safe induction
induction
safe
Prior art date
Application number
SG11202001458SA
Inventor
Myra Widjojoatmodjo
Olivier Godeaux
Kristi Williams
Benoit Callendret
Jerald Sadoff
Original Assignee
Janssen Vaccines & Prevention Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Vaccines & Prevention Bv filed Critical Janssen Vaccines & Prevention Bv
Publication of SG11202001458SA publication Critical patent/SG11202001458SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
SG11202001458SA 2017-09-15 2018-09-13 Method for the safe induction of immunity against rsv SG11202001458SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762558994P 2017-09-15 2017-09-15
PCT/EP2018/074710 WO2019053109A1 (en) 2017-09-15 2018-09-13 Method for the safe induction of immunity against rsv

Publications (1)

Publication Number Publication Date
SG11202001458SA true SG11202001458SA (en) 2020-03-30

Family

ID=63637887

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202001458SA SG11202001458SA (en) 2017-09-15 2018-09-13 Method for the safe induction of immunity against rsv

Country Status (14)

Country Link
US (2) US11229695B2 (en)
EP (1) EP3681533A1 (en)
JP (1) JP2020533367A (en)
KR (1) KR20200053518A (en)
CN (1) CN111163800A (en)
AU (1) AU2018333566A1 (en)
BR (1) BR112020004143A2 (en)
CA (1) CA3073790A1 (en)
EA (1) EA202090738A1 (en)
IL (1) IL273193B2 (en)
MX (1) MX2020002876A (en)
SG (1) SG11202001458SA (en)
WO (1) WO2019053109A1 (en)
ZA (1) ZA202001600B (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA035909B1 (en) 2015-07-07 2020-08-31 Янссен Вэксинс Энд Превеншн Б.В. Stabilized soluble pre-fusion rsv f polypeptides
CA2991002C (en) 2015-07-07 2023-11-28 Janssen Vaccines & Prevention B.V. Vaccine against rsv
BR112018070323A2 (en) 2016-04-05 2019-01-29 Janssen Vaccines & Prevention Bv rsv vaccine
ES2858315T3 (en) 2016-04-05 2021-09-30 Janssen Vaccines & Prevention Bv Stabilized soluble RSV prefusion protein F for use in the prophylaxis of RSV infection
IL264119B2 (en) 2016-05-30 2023-04-01 Janssen Vaccines Prevention B V Stabilized pre-fusion rsv f proteins
CA3061278A1 (en) * 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
US11229695B2 (en) * 2017-09-15 2022-01-25 Janssen Vaccines & Prevention B.V. Method for the safe induction of immunity against RSV
EA202193119A1 (en) * 2019-05-15 2022-02-18 Янссен Вэксинс Энд Превеншн Б.В. PREVENTIVE TREATMENT OF RESPIRATORY SYNCYTHIAL VIRUS INFECTION WITH ADENOVIRUS VACCINE
AU2020275455A1 (en) * 2019-05-15 2021-12-09 Janssen Vaccines & Prevention B.V. Co-administration of seasonal influenza vaccine and an adenovirus based respiratory syncytial virus vaccine
WO2022002894A1 (en) * 2020-06-29 2022-01-06 Janssen Vaccines & Prevention B.V. Vaccine combination against respiratory syncytial virus infection
CN112226444B (en) * 2020-08-25 2022-11-04 北京交通大学 Nucleotide sequence of fusion glycoprotein before full-length fusion of respiratory syncytial virus, recombinant adenovirus vector and application product thereof
CN112220921B (en) * 2020-08-25 2022-08-16 北京交通大学 Combined vaccine for respiratory syncytial virus infection

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
FR2705686B1 (en) 1993-05-28 1995-08-18 Transgene Sa New defective adenoviruses and corresponding complementation lines.
EP1548118A2 (en) 1994-06-10 2005-06-29 Genvec, Inc. Complementary adenoviral vector systems and cell lines
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
US5965541A (en) 1995-11-28 1999-10-12 Genvec, Inc. Vectors and methods for gene transfer to cells
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5837520A (en) 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
ATE278794T1 (en) 1995-06-15 2004-10-15 Crucell Holland Bv PACKAGING SYSTEMS FOR HUMAN, HUMAN ADENOVIRUSES, FOR USE IN GENE THERAPY
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
US5891690A (en) 1996-04-26 1999-04-06 Massie; Bernard Adenovirus E1-complementing cell lines
BR9710030A (en) 1996-07-01 1999-08-10 Rhone Poulenc Rorer Sa Process of production of recombinant adenoviruses process of purification of recombinant adenoviruses from a biological medium purified viral preparation pharmaceutical composition and use of iodixanol-5,5 '- [(2-Hydroxypropyl-1,3-Propanottl) -Bis [N, N'-Bis (2,3-Didroxypropyl-2,4,6-Triodo-1,3-Benzenocarboxamide]
FR2751343B1 (en) 1996-07-16 1998-12-18 Transgene Sa PROCESS FOR THE PRESERVATION OF INFECTIOUS RECOMBINANT VIRUSES, AQUEOUS VIRAL SUSPENSION, AND USE AS A MEDICAMENT
AU4255397A (en) 1996-09-06 1998-03-26 Trustees Of The University Of Pennsylvania, The Chimpanzee adenovirus vectors
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
CA2272820C (en) 1996-11-20 2012-09-11 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
US6261823B1 (en) 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
WO1998039411A1 (en) 1997-03-04 1998-09-11 Baxter International Inc. Adenovirus e1-complementing cell lines
US6020191A (en) 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
US6210683B1 (en) 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
PL197747B1 (en) 1998-02-17 2008-04-30 Schering Corp Compositions comprising viruses and methods for concentrating virus preparations
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
WO2000029024A1 (en) 1998-11-16 2000-05-25 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
US6225289B1 (en) 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
EP1550722B1 (en) 1999-05-17 2007-06-13 Crucell Holland B.V. Recombinant human adenovirus serotype 35
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
DE19955558C2 (en) 1999-11-18 2003-03-20 Stefan Kochanek Permanent amniocyte cell line, its production and use for the production of gene transfer vectors
CA2399321C (en) 2000-03-07 2013-04-30 Robert K. Evans Adenovirus formulations
MXPA02011018A (en) 2000-05-08 2004-08-19 Davisco Internat Foods Inc Enzymatic treatment of whey proteins for the production of antihypertensive peptides, the resulting products and treatment of hypertension in mammals.
AUPR878401A0 (en) 2001-11-09 2001-12-06 Biota Holdings Ltd Methods for identifying or screening anti-viral agents
CA2469623C (en) 2001-12-12 2012-05-29 F H Faulding & Co Limited Composition for the preservation of viruses
RU2004125283A (en) 2002-01-18 2005-06-10 Шеринг Акциенгезельшафт (De) STABILIZED Adenovirus Compositions
US20030180936A1 (en) 2002-03-15 2003-09-25 Memarzadeh Bahram Eric Method for the purification, production and formulation of oncolytic adenoviruses
SI1497440T1 (en) 2002-04-25 2009-02-28 Crucell Holland Bv Stable adenoviral vectors and methods for propagation thereof
EA010828B1 (en) 2002-04-25 2008-12-30 Круселл Холланд Б.В. Recombinant adenovirus vectors and methods for the production thereof and use
AU2003229060A1 (en) 2002-05-14 2003-12-02 Merck And Co., Inc. Methods of adenovirus purification
SE0202110D0 (en) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
EP1585964A4 (en) 2002-08-28 2008-07-16 Introgen Therapeutics Inc Chromatographic methods for adenovirus purification
SE0301998D0 (en) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
JP4814800B2 (en) 2004-01-23 2011-11-16 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー Chimpanzee adenovirus vaccine carrier
US20070207461A1 (en) 2004-02-23 2007-09-06 Crucell Holland B.V. Virus Purification Methods
CN101155915B (en) 2005-04-11 2013-12-04 克鲁塞尔荷兰公司 Virus purification using ultrafiltration
WO2007104792A2 (en) 2006-03-16 2007-09-20 Crucell Holland B.V. Recombinant adenoviruses based on serotype 26 and 48, and use thereof
WO2007110409A1 (en) 2006-03-27 2007-10-04 Crucell Holland B.V. Compositions comprising a recombinant adenovirus and an adjuvant
US8772256B2 (en) 2006-11-30 2014-07-08 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Codon modified immunogenic compositions and methods of use
US7901388B2 (en) 2007-07-13 2011-03-08 Bacoustics, Llc Method of treating wounds by creating a therapeutic solution with ultrasonic waves
MX2010007107A (en) 2007-12-24 2010-12-21 Id Biomedical Corp Quebec Recombinant rsv antigens.
WO2009117134A2 (en) 2008-03-21 2009-09-24 National Institutes Of Health Aerosolized genetic vaccines and methods of use
CN102203242B (en) 2008-11-03 2013-06-12 克鲁塞尔荷兰公司 Method for the production of adenoviral vectors
JP5882741B2 (en) 2009-02-02 2016-03-09 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Nucleic acid and amino acid sequences of simian adenovirus, vectors containing the same, and uses thereof
JP5796011B2 (en) 2009-06-24 2015-10-21 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム vaccine
AU2010264688A1 (en) 2009-06-24 2012-01-19 Glaxosmithkline Biologicals S.A. Recombinant RSV antigens
AR077757A1 (en) 2009-07-15 2011-09-21 Novartis Ag COMPOSITIONS OF FUSION PROTEINS OF RESPIRATORY SINCICIAL VIRUS (RSV) AND METHODS FOR PREPARATION
DK2464664T3 (en) 2009-08-13 2016-01-18 Crucell Holland Bv ANTIBODIES AGAINST HUMAN RESPIRATORY SYNCYTIAL VIRUS (RSV) AND METHODS FOR USING IT
ES2445713T3 (en) 2009-10-15 2014-03-04 Crucell Holland B.V. Process for adenovirus purification from high cell density cultures
US8460920B2 (en) 2009-10-15 2013-06-11 Crucell Holland B.V. Method for the purification of adenovirus particles
WO2011050168A2 (en) 2009-10-21 2011-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Rsv immunogens, antibodies and compositions thereof
CN102762721B (en) 2010-02-15 2015-03-11 克鲁塞尔荷兰公司 Method for the production of Ad26 adenoviral vectors
JP5744196B2 (en) 2010-07-09 2015-07-08 クルセル ホランド ベー ヴェー Anti-human respiratory polynuclear virus (RSV) antibodies and methods of use
ES2782119T3 (en) 2011-05-13 2020-09-10 Glaxosmithkline Biologicals Sa RSV prefusion F antigens
CA2864956C (en) 2012-03-12 2021-11-09 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
JP5845376B2 (en) 2012-03-22 2016-01-20 クルセル ホランド ベー ヴェー Vaccine against RSV
WO2014005643A1 (en) 2012-07-05 2014-01-09 Okairos Ag Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides
KR20220139415A (en) 2013-03-13 2022-10-14 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 Prefusion rsv f proteins and their use
US9738689B2 (en) 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
WO2014170258A1 (en) 2013-04-15 2014-10-23 Crucell Holland B.V. Human antibodies binding to rsv g proteins
EP2986637A1 (en) 2013-04-15 2016-02-24 Crucell Holland B.V. Human antibodies binding to rsv g protein
WO2014174018A1 (en) * 2013-04-25 2014-10-30 Crucell Holland B.V. Stabilized soluble prefusion rsv f polypeptides
CA2914792C (en) * 2013-06-17 2024-02-27 Crucell Holland B.V. Stabilized soluble pre-fusion rsv f polypeptides
JP6013654B2 (en) 2013-09-19 2016-10-25 クルセル ホランド ベー ヴェー Improved adenovirus formulation
BR112018070323A2 (en) * 2016-04-05 2019-01-29 Janssen Vaccines & Prevention Bv rsv vaccine
CA3061278A1 (en) * 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
US11229695B2 (en) * 2017-09-15 2022-01-25 Janssen Vaccines & Prevention B.V. Method for the safe induction of immunity against RSV

Also Published As

Publication number Publication date
CA3073790A1 (en) 2019-03-21
AU2018333566A1 (en) 2020-02-27
BR112020004143A2 (en) 2020-09-01
MX2020002876A (en) 2020-07-22
EP3681533A1 (en) 2020-07-22
US20200197509A1 (en) 2020-06-25
IL273193A (en) 2020-04-30
WO2019053109A1 (en) 2019-03-21
IL273193B (en) 2022-12-01
IL273193B2 (en) 2023-04-01
CN111163800A (en) 2020-05-15
EA202090738A1 (en) 2020-06-10
ZA202001600B (en) 2023-04-26
JP2020533367A (en) 2020-11-19
US11229695B2 (en) 2022-01-25
US20220133878A1 (en) 2022-05-05
KR20200053518A (en) 2020-05-18

Similar Documents

Publication Publication Date Title
ZA202001600B (en) Method for the safe induction of immunity against rsv
HK1251614A1 (en) Method for the treatment of malignancies
TWI563768B (en) Inductive charging cuing method and the system thereof
IL277281B (en) Combination products for the treatment of rsv
PL3519142T3 (en) Method for the surface treatment of an article
EP3571288A4 (en) Induction of protective immunity against antigens
HUE064441T2 (en) Installation, treatment module and method for the treatment of objects
ZA201806807B (en) Method for the treatment or prevention of osteoarthritis
SG10202001028QA (en) Method For The Treatment Or Prevention Of Infection-Related Immune Conditions Using A Composition Comprising IgM
ZA202001536B (en) Method for the treatment of wastewaters
IL260070B (en) Method for the preparation of substituted 2-aryl-ethanols
EP3661547A4 (en) Induction of protective immunity against antigens
KR101976358B9 (en) Safety improve method of robot
KR102003126B9 (en) Safety evaluation method of robot
HK1210590A1 (en) Method for the treatment of hypercholesterolemia
GB201600158D0 (en) Purification method
GB201715139D0 (en) Security Method
PL3098072T3 (en) Method for the production of laminates
IL271248A (en) Method for the treatment of immune thrombocytopenia
GB201806079D0 (en) Safe Steps
GB2553426B (en) Safety apparatus
GB201714775D0 (en) Safety apparatus
HUE056857T2 (en) Immunity inducer
GB201705192D0 (en) Safety apparatus
GB201603148D0 (en) Method for adjustung the length of an article